StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Spyre Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Spyre Therapeutics's profit margin for the twelve months ending Mar 31, 2024 was -52939.7%. For fiscal 2023 it was -38238.1%, against -3598.8% the year before. The highest annual figure on record is -351.1% in fiscal 2021.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-38238.1%−34639.4
FY2022Dec 31, 2022-3598.8%−3247.6
FY2021Dec 31, 2021-351.1%+789.5
FY2018Dec 31, 2018-1140.6%−617.4
FY2017Dec 31, 2017-523.3%−54.4
FY2016Dec 31, 2016-468.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2023Jun 30, 2023-31552.5%−27980.8
Q1 FY2023Mar 31, 2023-9304.0%−7509.9
Q4 FY2022Dec 31, 2022-11203.6%−10642.5
Q3 FY2022Sep 30, 2022-10479.3%−9027.8
Q2 FY2022Jun 30, 2022-3571.7%−3521.8
Q1 FY2022Mar 31, 2022-1794.1%−1398.2
Q4 FY2021Dec 31, 2021-561.1%−23.4
Q3 FY2021Sep 30, 2021-1451.5%−1014.4
Q2 FY2021Jun 30, 2021-49.9%+574.6
Q2 FY2018Jun 30, 2018-395.9%+52.5
Q1 FY2018Mar 31, 2018-537.7%+98.5
Q4 FY2017Dec 31, 2017-437.2%–
Q3 FY2017Sep 30, 2017-624.4%–
Q2 FY2017Jun 30, 2017-448.4%–
Q1 FY2017Mar 31, 2017-636.2%–

More Spyre Therapeutics figures

See a number that looks wrong?